Welcome to our dedicated page for Real Brokerage SEC filings (Ticker: REAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Real Brokerage Inc. (REAX) has upended the traditional real-estate model with its cloud platform, revenue-share economics and proprietary reZEN software. That innovation makes its SEC disclosures unusually rich: investors comb the filings for agent-count momentum, commission splits, technology spend and stock-based incentives—details buried in hundreds of pages.
This page delivers every document the instant it hits EDGAR, from the Real Brokerage annual report 10-K simplified to each Real Brokerage quarterly earnings report 10-Q filing. Stock Titan’s AI produces concise, plain-English summaries so understanding Real Brokerage SEC documents with AI feels as straightforward as reading a headline. Need to catch executive moves? Real Brokerage insider trading Form 4 transactions surface in real time, along with alerts covering Real Brokerage executive stock transactions Form 4 and Real Brokerage 8-K material events explained. You’ll also find the Real Brokerage proxy statement executive compensation and shelf registrations—all in one place.
With AI-powered highlights you can:
- Run a Real Brokerage earnings report filing analysis that tracks commission revenue trends quarter over quarter
- Monitor Real Brokerage Form 4 insider transactions real-time before market-moving announcements
- Quickly review board proposals inside the Real Brokerage proxy statement executive compensation section
Whether you’re modeling cash flows or assessing dilution risk, this library of Real Brokerage SEC filings explained simply turns hours of document hunting into minutes of insight.
Regencell Bioscience Holdings Limited (RGC) filed a Form 6-K with the U.S. SEC for the month of June 2025. The submission is largely administrative in nature and furnishes, pursuant to Nasdaq Rule 5250(c)(2), the company’s unaudited condensed consolidated interim balance sheets and statements of operations and comprehensive loss for the six-month period ended 31 December 2024. These financial statements are provided as Exhibit 99.1, titled “Regencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results.” No detailed line-item financial data, earnings guidance, or strategic initiatives are included in the body of the filing. The document also contains standard signature and filing-cover information confirming that Regencell continues to file its annual reports on Form 20-F.
Because the actual financial tables are presented only in the attached exhibit and not within the filing text supplied, investors will need to review Exhibit 99.1 separately to evaluate revenue trends, profitability, liquidity, or other key performance indicators. Overall, the filing appears routine and does not announce any major transactions, capital raises, or changes in corporate governance.
Royal Bank of Canada (RY) has filed a 424B2 preliminary pricing supplement for Senior Global Medium-Term Notes, Series J—Market Linked Securities that are Auto-Callable with a Contingent Coupon and Contingent Downside. The $1,000-denominated notes are linked to the lowest performing of The Goldman Sachs Group, Inc. (GS), Meta Platforms, Inc. (META) and Exxon Mobil Corporation (XOM).
Holders will receive a quarterly coupon of at least 21.00% per annum provided the worst-performing stock on the observation date is at or above 70 % of its initial level. Beginning January 2026, the notes are automatically called if the worst-performer is at or above its starting value, returning par plus the coupon. If not called, maturity is 21 Jul 2028.
Principal is at risk: if, on the final observation date (18 Jul 2028), the worst-performing stock closes below 70 % of its start value, repayment is reduced one-for-one with the decline, exposing investors to losses up to 100 %. Investors do not share in stock appreciation and forgo all dividends.
The preliminary estimated value is $910–$960 per $1,000 note, below the offering price, reflecting dealer discount of $23.25 and additional concessions of up to $2.00. The notes are senior unsecured obligations of RBC, carry full credit risk of the bank, are not FDIC/CDIC insured, are not bail-inable, and will not be exchange-listed, limiting liquidity.
Form 144 Notice of Proposed Sale filed for Real Brokerage (NASDAQ: REAX) indicates insider selling activity by Tamir Poleg. The filing details a proposed sale of 124,377 shares with an aggregate market value of $499,810.79, to be executed through Morgan Stanley Smith Barney LLC.
Notable details from the filing:
- Securities were acquired through stock option exercise on June 18, 2025
- Total outstanding shares: 206,200,000
- Planned execution date: June 18, 2025
- Trading venue: NASDAQ
The filing also reveals significant recent selling activity by Poleg over the past 3 months, totaling approximately 741,692 shares worth over $3.2 million through multiple transactions between March and June 2025. The largest single transaction was 126,520 shares sold on March 24, 2025, for $571,150.80.
FAQ
What is the current stock price of Real Brokerage (REAX)?
What is the market cap of Real Brokerage (REAX)?
What core services does Real Brokerage Inc offer?
How does the company utilize technology in its operations?
What is the significance of the reZEN platform?
Which markets does Real Brokerage primarily operate in?
How does Real Brokerage differentiate itself from competitors?
What are the key business segments of Real Brokerage?
How do integrated financial services play a role in the company’s value proposition?
What should investors understand about the company’s technology emphasis?
